## (19) World Intellectual Property Organization International Bureau





(43) International Publication Date 15 September 2005 (15.09.2005)

PCT

## (10) International Publication Number WO 2005/084656 A1

- (51) International Patent Classification7: A61K 31/166, A61P 29/00
- (21) International Application Number:

PCT/GB2005/000780

- (22) International Filing Date: 2 March 2005 (02.03.2005)
- (25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

60/549,143

3 March 2004 (03.03.2004) US

- (71) Applicant (for all designated States except US): BI-OLIPOX AB [SE/SE]; P.O. Box 6280, S-102 34 Stockholm (SE).
- (72) Inventors; and
- (72) Inventors; and
  (75) Inventors/Applicants (for US only): OLOFSSON,
  Kristofer [SE/SE]; Biolipox AB, P.O. Box 6280, S-102
  34 Stockholm (SE). PELCMAN, Benjamin [SE/SE];
  Biolipox AB, P.O. Box 6280, S-102 34 Stockholm (SE).
  NILSSON, Peter [SE/SE]; Biolipox AB, P.O. Box 6280,
  S-102 34 Stockholm (SE). SCHAAL, Wesley [US/SE];
  Biolipox AB, P.O. Box 6280, S-102 34 Stockholm (SE).
  HALLBERG, Anders [SE/SE]; Department of Medicinal
  Chemistry, Biomedical Centre, Uppsala University, P.O.
  Box 574, S-751 23 Uppsala (SE).

  (54) Title: USE OF NEW LIPOXYGENASE INHIBITORS

  (57) Abstract: There is provided a use of a compound of formula (I), wherein R¹, R², R³ and R⁴ have meanings given in the description, and pharmaceutically-acceptable salts thereof, for the manufacture of a medicament for the treatment of a disease in which inhibition of the activity of a lipoxygenase (e.g. 15-lipoxygenase) is desired and/or required, and particularly in the treatment of (75) Inventors/Applicants (for US only): OLOFSSON.

- (74) Agents: MCNEENEY, Stephen et al.; Eric Potter Clarkson, Park View House, 58 The Ropewalk, Nottingham NG1
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,

scription, and pharmaceutically-acceptable salts thereof, for the manufacture of a medicament for the treatment of a disease in which inhibition of the activity of a lipoxygenase (e.g. 15-lipoxygenase) is desired and/or required, and particularly in the treatment of inflammation.